Financial Position - As of December 31, 2025, MBX Biosciences reported unaudited cash, cash equivalents, and marketable securities of $373.7 million, expected to fund operations into 2029[6]. - The company estimates that its current cash resources may be exhausted sooner than expected due to underlying assumptions[10]. Business Development - The company plans to expand its obesity portfolio in 2026 with two additional obesity candidates, with nominations anticipated in Q2 and Q3 2026[9]. - Forward-looking statements include expectations regarding the timing of additional obesity candidates and financial results, which are subject to risks and uncertainties[11]. Audit and Compliance - The ongoing audit of the consolidated financial statements for the year ended December 31, 2025, may result in changes to the reported financial information[6]. - The financial results will be reflected in the audited consolidated financial statements for the fiscal year ended December 31, 2025[12]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[5]. Risks - Risks include the company's reliance on third parties for clinical trials and product development, as well as the need for substantial additional funds for commercialization[12]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[5]. Press Release - The press release regarding the 2026 outlook and business update was issued on January 11, 2026[7].
MBX Biosciences, Inc.(MBX) - 2025 Q4 - Annual Results